DYDavid Yudovich

David Yudovich

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


David Yudovich has a total of 16 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Lysine-specific demethylase 1A restricts ex vivo propagation of human HSCs and is a target of UM171

    by Agatheeswaran Subramaniam, Kristijonas Žemaitis, Mehrnaz Safaee Talkhoncheh, David Yudovich, Alexandra Bäckström, Shubhranshu Debnath, Jun Chen, Mayur Vilas Jain, Roman Galeev, Massimiliano Gaetani, et al.

    Culture conditions in which hematopoietic stem cells (HSCs) can be expanded for clinical benefit are highly sought after. Here, we report that inhibition of the epigenetic regulator lysine-specific histone demethylase 1A (LSD1) induces a rapid expansion of human cord blood–derived CD34+ cells and promotes in vitro propagation of long-term repopulating HSCs by preventing differentiation. The phenotype and molecular characteristics of cells treated with LSD1 inhibitors were highly similar to cells treated with UM171, an agent promoting expansion of HSCs through undefined mechanisms and currently being tested in clinical trials. Strikingly, we found that LSD1, as well as other members of the LSD1-containing chromatin remodeling complex CoREST, is rapidly polyubiquitinated and degraded upon UM171 treatment. CRISPR (clustered regularly interspaced short palindromic repeats)/Cas9 depletion of the CoREST core member, RCOR1, resulted in expansion of CD34+ cells similar to LSD1 inhibition and UM171. Taken together, LSD1 and CoREST restrict HSC expansion and are principal targets of UM171, forming a mechanistic basis for the HSC-promoting activity of UM171.


  • Open Access

    Efficient and nontoxic biomolecule delivery to primary human hematopoietic stem cells using nanostraws

    by Ludwig Schmiderer, Agatheeswaran Subramaniam, Kristijonas Žemaitis, Alexandra Bäckström, David Yudovich, Svetlana Soboleva, Roman Galeev, Christelle N. Prinz, Jonas Larsson, Martin Hjort

    Significance: Primary stem cells are difficult to transfect, and their viability and function are impaired by traditional transfection methods. We show that nanostraws can be used to deliver RNA to primary human hematopoietic stem cells without any detectable negative effects. Nanostraw-treated cells show no alterations in gene expression and fully retain their proliferative capacity and their potential to regenerate blood cells of different lineages in vivo. This nonperturbative transfection method can benefit functional studies and clinical applications where minimal impact on stem cell function and viability is required.